VVOS - Vivos stock surges ~30% on acquiring dental product rights from Advanced Facialdontics
- Vivos Therapeutics ( NASDAQ: VVOS ) acquired certain U.S. and international patents, product rights, and other intellectual property (IP) from Advanced Facialdontics (AFD).
- Vivos said AFD's main product, Preventive Oral Device, known as the POD, has FDA 510(k) clearance to treat patients in the U.S. and Canada with Temporomandibular Joint Dysfunction (TMD) and/or Bruxism (teeth grinding or clenching), both of which are known to be associated with obstructive sleep apnea (OSA).
- AFD's second FDA 510(k) cleared product is a an oral appliance called Night Block.
- Vivos noted that the acquisition of these novel technologies will help it in providing complementary products to patients with OSA who experience pain, headaches, tooth loss, and other symptoms linked with TMD and Bruxism.
- Vivos expects to manufacture the AFD products via existing manufacturing relationships.
- In connection with this transaction, Scott Simonetti, AFD Founder, CEO and the inventor of the acquired patents, was appointed as Vivos' new Senior Director of Research and Product Development, the company added .
- VVOS +32.79% to $0.81 premarket March 1
For further details see:
Vivos stock surges ~30% on acquiring dental product rights from Advanced Facialdontics